B
Bullisch
Bullisch · 25%PHVS
$32.16
Szenariopreis
$31.410
+0.748 (+2.38%)Zum Schluss
Loading chart…
- Hoch
- 32.120
- Eröffnung
- 31.570
- Volumengewichteter Durchschnittskurs
- 31.26
- Volumen
- 621.71K
- Marktkap.
- 969.24M
- Tief
- 30.250
- Umsatz
- 19.43M
- EV/EBITDA, TTM
- 0.00
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
KI-Analyse of Pharvaris NV (PHVS)
KaufenPharvaris NV (PHVS) is a good buy right now due to its recent Phase 3 trial success for its drug deucrictibant, which achieved an 83% reduction in monthly HAE attacks. The stock has shown strong momentum with a 5-day change of +13.23% and a current RSI of 61.35, suggesting bullish momentum. Additionally, analysts have set a price target range of $40 to $65, indicating potential upside of 27% to 106% from the current price. The main risk is the company's ongoing net losses, which totaled €47.8 million in Q2 2026, reflecting the need for continued financial improvement.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Pharvaris NV (PHVS) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -6.58.
Alphio-AI-Kursszenarien für PHVS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die PHVS halten
Event-Zeitleiste
News
6.010-23CNBCLatest Wall Street Rating Updates
9.509-09NASDAQ.COMPharvaris N.V. Phase 3 Trial Success for Deucrictibant
5.009-09stocktwitsBioCryst's Orladeyo Approved for HAE Attack Prevention
9.509-08stocktwitsRoivant and Pharvaris Achieve Clinical Trial Success
9.509-08Yahoo FinanceBiotech Stocks Hit All-Time Highs Following Positive Trial Results
PHVS FAQ – beantwortet von Alphio AI
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet. It operates in the Healthcare sector.
Pharvaris NV (PHVS) is a good buy right now due to its recent Phase 3 trial success for its drug deucrictibant, which achieved an 83% reduction in monthly HAE attacks. The stock has shown strong momentum with a 5-day change of +13.23% and a current RSI of 61.35, suggesting bullish momentum. Additionally, analysts have set a price target range of $40 to $65, indicating potential upside of 27% to 106% from the current price. The main risk is the company's ongoing net losses, which totaled €47.8 million in Q2 2026, reflecting the need for continued financial improvement.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.